Dermatology News

• Study Links Obesity to Biologic Failure in Psoriasis A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in patients with psoriasis.
  Medscape Medical News, April 07, 2025
• Alert FDA Approves First and Only Therapy for IgG4-RD The CD19+ B-Cell targeted therapy reduced flare risk by 87% in a phase 3 clinical trial.
  Medscape Medical News, April 04, 2025
• AAD 2025 Surgeon Reviews Options for Superficial Skin Cancer For superficial skin cancers, Mohs surgery can be a definitive procedure, but nonsurgical approaches are competitive in the context of practical considerations, such as patient preferences and costs.
  Medscape Medical News, April 04, 2025
• How Office Props Improve Patient Outcomes Showing patients props and other visual aids improves recall of information, motivates patients, said doctors who have expanded their ‘black bags.’
  Medscape Medical News, April 04, 2025
• Many With HS Unaware of FDA-Approved Treatments: Survey A national survey reveals that most individuals with hidradenitis suppurativa are unaware of US Food and Drug Administration-approved treatments and not satisfied with their current treatment.
  Medscape Medical News, April 04, 2025
• Early-Onset Atopic Dermatitis Raises Uveitis Risk in Kids A cohort study finds children with early-onset atopic dermatitis to be at increased risk for uveitis, highlighting a need for ophthalmologic monitoring in youth.
  Medscape Medical News, April 04, 2025
• Secukinumab May Protect Against Bone Erosion in PsA Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic arthritis, according to results from a randomized controlled trial.
  Medscape Medical News, April 04, 2025
• WCM-EADO 2025 Population vs Tailored Skin Cancer Screening: Which Is Best? Broad-based skin cancer screening may strain healthcare resources and lead to overdiagnosis, but it may also help catch more skin cancers earlier. Experts debate the pros and cons.
  Medscape Medical News, April 04, 2025
• PBM Private Labeling Boosts Biosimilars, Raises Concerns Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this consolidation of the drug supply chain could undercut competition.
  Medscape Medical News, April 03, 2025
• AAD 2025 TYK2 Inhibitors Show Impressive Efficacy for Psoriasis Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque psoriasis, with one producing a PASI90 response in 61% of patients at 52 weeks.
  Medscape Medical News, April 03, 2025
• Ruxolitinib Shows Consistent Results Across Vitiligo Groups Ruxolitinib cream is effective and safe for treating vitiligo across different subgroups of patients, according to phase 3 studies.
  Medscape News UK, April 03, 2025
• Pityriasis Rosea Before 15 Weeks May Up Pregnancy Risks A retrospective review reports that pregnant women with pityriasis rosea onset before 15 weeks have higher rates of unfavorable outcomes.
  Medscape Medical News, April 03, 2025
• New Level of Evidence Ties Shingles Vax to Lower Dementia Risk A novel study shows that the live-attenuated varicella zoster vaccine may protect against dementia in older adults.
  Medscape Medical News, April 02, 2025
• Pembrolizumab Shows Promise in Two CTCL Subtypes Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly half of patients in a case series.
  Medscape Medical News, April 02, 2025
• Low Geographic, Racial Diversity Persists in Myositis Trials Most myositis trials have few non-White participants; however, diversity is improving. Trials lack sites in South/Central America, Africa, and Southeast Asia, highlighting geographic disparities.
  Medscape Medical News, April 02, 2025
• Measles Cases in Texas Rise to 422, State Health Department Says The Texas health department reported 422 cases of measles in the state on Tuesday, an increase from 400 on March 28, as the United States battles one of the largest...
  Reuters Health Information, April 01, 2025
• AAD 2025 Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib in a new trial shows that efficacy extends to cutaneous lupus.
  Medscape Medical News, April 01, 2025
• ELCC 2025 Skin Care Regimen Cuts Toxicities of Combo NSCLC Therapy A preventative and proactive dermatologic regimen reduces skin and nail adverse reactions in patients with EGFR-mutant NSCLC receiving first-line treatment with amivantamab plus lazertinib.
  Medscape Medical News, April 01, 2025
• US FDA Approves Freeze-dried Version of Bavarian Nordic's Mpox, Smallpox Vaccine Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.
  Reuters Health Information, March 31, 2025
• Can Repurposed Smallpox Vaccine Prove Effective for Mpox? The modified vaccinia Ankara-Bavarian Nordic vaccine, originally approved for smallpox, is safe and well tolerated in at-risk individuals, with one dose offering protection against mpox.
  Medscape News UK, March 31, 2025